Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs

被引:21
作者
Kandimalla, ER [1 ]
Zhu, FG [1 ]
Bhagat, L [1 ]
Yu, D [1 ]
Agrawal, S [1 ]
机构
[1] Hybridon Inc, Cambridge, MA 02139 USA
关键词
CpG DNA; cytokines; immunostimulation; oligonucleotide; phosphorothioate; TLR9;
D O I
10.1042/BST0310654
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bacterial and synthetic DNA containing unmethylated 2'-deoxyribo(cytidine-phosphate-guanosine) (CpG) dinucleotides in specific sequence contexts activate the vertebrate innate immune system. A molecular pattern recognition receptor, Toll-like receptor 9 (TLR9), recognizes CpG DNA and initiates the signalling cascade, although a direct interaction between CpG DNA and TILR9 has not been demonstrated yet. TLR9 in different species exhibits sequence specificity. Our extensive structure-immunostimulatory activity relationship studies showed that a number of synthetic pyrimidine (Y) and purine (R) nucleotides are recognized by the receptor as substitutes for the natural nucleotides deoxycytidine and deoxyguanosine in a CpG dinucleotide. These studies permitted development of synthetic YpG, CpR and YpR immunostimulatory motifs, and showed divergent nucleotide motif recognition pattern of the receptor. Surprisingly, we found that synthetic immunostimulatory motifs produce different cytokine induction profiles compared with natural CpG motifs. Importantly, we also found that some of these synthetic immunostimulatory motifs show optimal activity in both mouse and human systems without the need to change sequences, suggesting an overriding of the species-dependent specificity of the receptor by the use of synthetic motifs. in the present paper, we review current understanding of structural recognition and functional modulation of TILR9 receptor by second-generation synthetic CpG DNAs and their potential application as wide-spectrum therapeutic agents.
引用
收藏
页码:654 / 658
页数:5
相关论文
共 29 条
[1]   Medicinal chemistry and therapeutic potential of CpG DNA [J].
Agrawal, S ;
Kandimalla, ER .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (03) :114-121
[2]   Antisense and/or Immunostimulatory Oligonucleotide Therapeutics [J].
Agrawal, Sudhir ;
Kandimalla, Ekambar R. .
CURRENT CANCER DRUG TARGETS, 2001, 1 (03) :197-209
[3]  
Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
[4]  
2-U
[5]   Mammalian Toll-like receptors [J].
Akira, S .
CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (01) :5-11
[6]   Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[7]   Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition [J].
Bauer, S ;
Kirschning, CJ ;
Häcker, H ;
Redecke, V ;
Hausmann, S ;
Akira, S ;
Wagner, H ;
Lipford, GB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9237-9242
[8]   CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents [J].
Bhagat, L ;
Zhu, FG ;
Yu, D ;
Tang, J ;
Wang, H ;
Kandimalla, ER ;
Zhang, RW ;
Agrawal, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 300 (04) :853-861
[9]   Immunopharmacology of CpG DNA [J].
Dalpke, A ;
Zimmermann, S ;
Heeg, K .
BIOLOGICAL CHEMISTRY, 2002, 383 (10) :1491-1500
[10]   A Toll-like receptor recognizes bacterial DNA [J].
Hemmi, H ;
Takeuchi, O ;
Kawai, T ;
Kaisho, T ;
Sato, S ;
Sanjo, H ;
Matsumoto, M ;
Hoshino, K ;
Wagner, H ;
Takeda, K ;
Akira, S .
NATURE, 2000, 408 (6813) :740-745